Cabio Biotech (Wuhan) Co., Ltd. (SHA:688089)

Cabio Biotech (Wuhan) Revenue

Cabio Biotech (Wuhan) had revenue of 121.30M CNY in the quarter ending September 30, 2025, a decrease of -3.97%. This brings the company's revenue in the last twelve months to 596.47M, up 17.85% year-over-year. In the year 2024, Cabio Biotech (Wuhan) had annual revenue of 555.59M with 25.19% growth.

• Revenue (ttm): 596.47M
• Revenue Growth: +17.85%
• P/S Ratio: 5.69
• Revenue / Employee: 1.06M
• Employees: 565
• Market Cap: 3.39B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	555.59M	111.79M	25.19%
Dec 31, 2023	443.80M	10.38M	2.39%
Dec 31, 2022	433.42M	82.32M	23.44%
Dec 31, 2021	351.11M	27.65M	8.55%
Dec 31, 2020	323.46M	11.91M	3.82%